SOFIVA GENOMICS Co (ROCO:6615) EBIT : NT$23.9 Mil (TTM As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is SOFIVA GENOMICS Co EBIT?

SOFIVA GENOMICS Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was NT$1.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was NT$23.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. SOFIVA GENOMICS Co's annualized ROC % for the quarter that ended in Sep. 2024 was -8.18%. SOFIVA GENOMICS Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 3.03%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. SOFIVA GENOMICS Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 3.12%.

SOFIVA GENOMICS Co EBIT Historical Data

The historical data trend for SOFIVA GENOMICS Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SOFIVA GENOMICS Co EBIT Chart

SOFIVA GENOMICS Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

77.18

39.24

65.43

48.84

10.19

SOFIVA GENOMICS Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															4.48	-3.25	14.61	11.21	1.31

Competitive Comparison of SOFIVA GENOMICS Co's EBIT

For the Diagnostics & Research subindustry, SOFIVA GENOMICS Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SOFIVA GENOMICS Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SOFIVA GENOMICS Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SOFIVA GENOMICS Co's EV-to-EBIT falls into.

SOFIVA GENOMICS Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$23.9 Mil.

SOFIVA GENOMICS Co (ROCO:6615) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

SOFIVA GENOMICS Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-27.916 * ( 1 - -70.1% )	/	( (583.393	+	578.041)	/ 2 )
=	-47.485116	/	580.717
=	-8.18 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	775.842	-	69.032	-	( 123.417	-	max(0, 89.569	-	280.979	+	123.417	))
=	583.393

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	776.491	-	62.267	-	( 136.183	-	max(0, 83.345	-	276.024	+	136.183	))
=	578.041

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

SOFIVA GENOMICS Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	5.256	/	( ( (113.213 + max(61.086, 0))	+	(111.894 + max(60.409, 0)) )	/	2 )
=	5.256	/	( ( 174.299	+	172.303 )	/	2 )
=	5.256	/	173.301
=	3.03 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(70.472	+	46.351	+	17.872)	-	(69.032	+	0	+	4.577)
=	61.086

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(57.782	+	51.361	+	18.272)	-	(62.267	+	0	+	4.739)
=	60.409

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

SOFIVA GENOMICS Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	23.874	/	764.278
	=	3.12 %

SOFIVA GENOMICS Co EBIT Related Terms

Thank you for viewing the detailed overview of SOFIVA GENOMICS Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

SOFIVA GENOMICS Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SOFIVA GENOMICS Co Ltd (ROCO:6615) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 66-1, Sec. 1, Chongqing S. Road, 4th Floor, Zhongzheng District, Taipei, TWN, 10043

Website

https://www.sofivagenomics.com.tw

SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, pre-natal and neonatal genetic testing and medical testing and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.

SOFIVA GENOMICS Co Headlines

No Headlines